SHL Telemedicine's SmartHeart® Technology Shows Remarkable Effects in Mayo Clinic and Imperial College London Trials
Key highlights from the presentation of the initial results include:
- Key highlights from the presentation of the initial results include:
A staggering decrease of- 27.5% in emergency room visits in the TELE-ACS trial1. - Erez Nachtomy, CEO of SHL Telemedicine, commented, "The initial results from the HELP-MI and TELE-ACS trials have surpassed our expectations.
- We are extremely confident in the potential of our SmartHeart® technology, and these findings further validate its efficacy in post-MI patient care.
- We are looking forward to the continued positive impact our technology will have on telemedicine and remote patient care."